

## SEQUENCE LISTING

<110> The Government of the United States of America as

<120> A recombinant vector expressing multiple constimulatory  
molecules and uses thereof

<130> 20264292PC

<140> TBA

<141> 1999-11-12

<150> 60/111,582

<151> 1998-12-09

<160> 41

<170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 1

Lys Thr Trp Gly Gln Tyr Trp Glx Tyr

1

5

<210> 2

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 2

Ile Thr Asp Gln Val Pro Pro Ser Val

1

5

<210> 3

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 3

Tyr Leu Glu Pro Gly Pro Val Thr Ala

1

5

<210> 4

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 4

Leu Leu Asp Gly Thr Ala Thr Leu Arg Leu

1

5

10

<210> 5

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 5

Val Leu Tyr Arg Tyr Gly Ser Phe Ser Val

```
<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence
```

**<220>**

<220>  
<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

```
<400> 6
Ala Ala Gly Ile Gly Ile Leu Thr Val
      1               5
```

```
<210> 7
<211> 9
<212> PRT
<213> Artificial Sequence
```

<220>

<220>  
<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 7  
Ile Leu Thr Val Ile Leu Gly Val Leu  
1 5

```
<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence
```

<220>

<220>  
<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 8  
Met Ser Leu Gln Arg Gln Phe Leu Arg

5

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

Met Leu Leu Ala Val Leu Tyr Cys Leu  
1 5

<211> 9

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

Tyr Met Asn Gly Thr Met Ser Gln Val  
1 5

<211> 9

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

Ser Glu Ile Trp Arg Asp Ile Asp Phe

5

**<220>**

<400> 12  
Ala Phe Leu Pro Trp His Arg Leu Phe  
1 5

<220>

<400> 13  
Gln Asn Ile Leu Leu Ser Asn Ala Pro Leu Gly Pro Gln Phe Pro  
1 5 10 15

**<220>**

<400> 14  
Ser Tyr Leu Gln Asp Ser Asp Pro Asp Ser Phe Gln Asp

10

<213> Artificial Sequence

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

5

<213> Artificial Sequence

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

5

<213> Artificial Sequence

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

Glu Val Asp ~~Pro~~ Ile Gly His Leu Tyr

5

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

Phe Leu Trp Gly Pro Arg Ala Leu Val  
1 5

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

Ala Ala Arg Ala Val Phe Leu Ala Leu  
1 5

**<220>**

<223> Description/ of Artificial Sequence: SYNTHETIC  
PEPTIDE

Tyr Arg Pro Arg/Pro Arg Arg Tyr

.5

<213> Artificial Sequence

**<220>**

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

Val Leu Pro Asp Val Phe Ile Arg Cys

5

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

Ala Tyr Gly Leu Asp ~~Phe~~ Tyr Ile Leu

5

<213> Artificial Sequence

**<220>**

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

Tyr Leu Ser Gly Ala Asn Leu Asn Leu



1

5

<210> 24

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 24

Tyr Leu Ser Gly Ala Asp Leu Asn Leu

1

5

<210> 25

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 25

Ser Tyr Leu Asp Ser Gly Ile His Phe

1

5

<210> 26

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 26

Glu Glu Lys Leu Ile Val Val Leu Phe

5

<213> Artificial Sequence

**<220>**

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

10

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

5

<213> Artificial Sequence

**<220>**

**<220>**

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

Lys Ile Phe|Gly Ser Leu Ala Phe Leu

[illegible]

5

**<220>**

<220>  
<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 30  
Tyr Met Leu Asp Leu Gln Pro Glu Thr Thr  
1 5 10

```
<210> 31
<211> 20
<212> PRT
<213> Artificial Sequence
```

<220>

<220>  
<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 31  
Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly  
1 5 10 15

Val Thr Ser Ala  
20

```
<210> 32
<211> 30
<212> PRT
<213> Artificial Sequence
```

**<220>**

<220>  
<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 32

Phe Leu Thr Pro Lys Lys Leu Gln Cys Val Asp Leu His Val Ile Ser  
1 5 10 15

Asn Asp Val Cys Ala Gln Val His Pro Gln Lys Val Thr Lys  
20 25 30

<210> 33

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 33

Phe Leu Thr Pro Lys Lys Leu Gln Cys Val  
1 5 10

<210> 34

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 34

Lys Leu Gln Cys Val Asp Leu His Val  
1 5

<210> 35

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

[illegible]

<400> 35

<210> 36

<212> PRT

<213> Artificial Sequence

<220>

<400> 36

<210> 37

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<220>

<400> 37

<210> 38

<211> 8

<212> PRT

<213> Artificial Sequence

**<220>**



Case	Age	Sex	Duration of disease	Site of lesion	Pathological findings	Response to treatment
1	45	M	10 years	Right frontal lobe	Large, well-circumscribed, solid, enhancing mass	Complete remission
2	52	F	5 years	Left parietal lobe	Large, well-circumscribed, solid, enhancing mass	Complete remission
3	60	M	3 years	Right parietal lobe	Large, well-circumscribed, solid, enhancing mass	Complete remission
4	58	F	8 years	Left frontal lobe	Large, well-circumscribed, solid, enhancing mass	Complete remission
5	65	M	12 years	Right frontal lobe	Large, well-circumscribed, solid, enhancing mass	Complete remission
6	70	F	15 years	Left parietal lobe	Large, well-circumscribed, solid, enhancing mass	Complete remission
7	75	M	18 years	Right parietal lobe	Large, well-circumscribed, solid, enhancing mass	Complete remission
8	80	F	20 years	Left frontal lobe	Large, well-circumscribed, solid, enhancing mass	Complete remission
9	85	M	22 years	Right frontal lobe	Large, well-circumscribed, solid, enhancing mass	Complete remission
10	90	F	25 years	Left parietal lobe	Large, well-circumscribed, solid, enhancing mass	Complete remission

<400> 41

15